Artivion (AORT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
Annual meeting scheduled for May 12, 2026, at 9:00 a.m. Eastern Time, to be held virtually.
Proxy materials, including the Notice, Proxy Statement, proxy card, and Annual Report, are available online for review and voting.
Shareholders can vote online, by phone, by mail, or virtually at the meeting.
Voting matters and shareholder proposals
Election of nine directors: Thomas F. Ackerman, Daniel J. Bevevino, Marna P. Borgstrom, James W. Bullock, Jeffrey H. Burbank, Elizabeth A. Hoff, J. Patrick Mackin, Jon W. Salveson, and Anthony B. Semedo.
Advisory (non-binding) vote to approve compensation of Named Executive Officers as disclosed in the proxy materials.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies may vote on other matters that may properly come before the meeting at their discretion.
Board of directors and corporate governance
Board recommends voting for all director nominees and for all proposals presented.
Instructions provided for withholding authority for individual director nominees.
Latest events from Artivion
- Proxy covers director elections, executive pay, auditor ratification, and ESG priorities.AORT
Proxy filing1 Apr 2026 - AMDS and On-X drive growth, with NEXUS acquisition and margin expansion on the horizon.AORT
Oppenheimer 36th Annual Healthcare MedTech & Services Conference17 Mar 2026 - Double-digit revenue and EBITDA growth in 2025 with strong 2026 outlook and clinical momentum.AORT
Q4 202512 Feb 2026 - Q2 revenue up 10% and adjusted EBITDA up 35%, with raised full-year guidance and improved liquidity.AORT
Q2 20242 Feb 2026 - Double-digit growth and margin expansion driven by innovation in aortic disease solutions.AORT
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Q3 revenue up 10% and adjusted EBITDA up 28%, led by product and international growth.AORT
Q3 202415 Jan 2026 - AMDS and global expansion drive double-digit growth and margin gains through 2025.AORT
Stifel 2024 Healthcare Conference13 Jan 2026 - Q1 revenue up 2% (4% constant currency), guidance raised, and product growth outpaced services.AORT
Q1 202527 Dec 2025 - AMDS launch, On-X growth, and margin expansion drive a robust outlook amid minimal macro risks.AORT
Oppenheimer 35th Annual Health Care MedTech and Services Conference26 Dec 2025